Abstract
The adenosine A2A receptor (A2AR) is highly concentrated in the striatum, and a therapeutic target for Parkinson’s disorder (PD) and Huntington’s disease. High affinity and selective radiolabeled A2AR antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A2A antagonists non-invasively in the brain. However, till date no complete review on A2AR PET ligands is available. The present article has been therefore focused on available PET tracers for A2AR and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A2ARs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A2AR for PD has also been presented.
Keywords: Adenosine A2A receptor, Parkinson’s disorder, positron emission tomography (PET), xanthine ligands, nonxanthine ligands, SCH442416, TMSX, 6-OHDA PD model.
Current Medicinal Chemistry
Title:Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Volume: 21 Issue: 3
Author(s): S. Khanapur, A. van Waarde, K. Ishiwata, K. L. Leenders, R. A.J.O. Dierckx and P. H. Elsinga
Affiliation:
Keywords: Adenosine A2A receptor, Parkinson’s disorder, positron emission tomography (PET), xanthine ligands, nonxanthine ligands, SCH442416, TMSX, 6-OHDA PD model.
Abstract: The adenosine A2A receptor (A2AR) is highly concentrated in the striatum, and a therapeutic target for Parkinson’s disorder (PD) and Huntington’s disease. High affinity and selective radiolabeled A2AR antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A2A antagonists non-invasively in the brain. However, till date no complete review on A2AR PET ligands is available. The present article has been therefore focused on available PET tracers for A2AR and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A2ARs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A2AR for PD has also been presented.
Export Options
About this article
Cite this article as:
Khanapur S., Waarde van A., Ishiwata K., Leenders L. K., Dierckx A.J.O. R. and Elsinga H. P., Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers, Current Medicinal Chemistry 2014; 21 (3) . https://dx.doi.org/10.2174/09298673113206660265
DOI https://dx.doi.org/10.2174/09298673113206660265 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Developing Ophthalmic Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Current Stem Cell Research & Therapy Vascular effects of flavonoids
Current Medicinal Chemistry Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Nitric Oxide and Dietary Factors: Part I Nitric Oxide Synthesis and Action
Vascular Disease Prevention (Discontinued) Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Fabrication and Characterization of Ocular Phase Transition Systems for Blepharitis: A Novel Approach
Drug Delivery Letters Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Current Pharmaceutical Design Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Role of Coronary Collaterals in Chronic Total Occlusions
Current Cardiology Reviews Individual Triptan Selection in Migraine Attack Therapy
Recent Patents on CNS Drug Discovery (Discontinued)